UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $497,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 24.6% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 142,131 shares of the biopharmaceutical company’s stock after selling 46,329 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.12% of Fate Therapeutics worth $497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Deerfield Management Company L.P. Series C increased its position in Fate Therapeutics by 62.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,555,871 shares of the biopharmaceutical company’s stock worth $11,663,000 after purchasing an additional 1,365,463 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Fate Therapeutics by 100.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,130,280 shares of the biopharmaceutical company’s stock worth $6,987,000 after buying an additional 1,067,101 shares during the period. Integral Health Asset Management LLC raised its stake in shares of Fate Therapeutics by 325.0% during the second quarter. Integral Health Asset Management LLC now owns 850,000 shares of the biopharmaceutical company’s stock worth $2,788,000 after buying an additional 650,000 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Fate Therapeutics in the second quarter valued at approximately $1,799,000. Finally, Perceptive Advisors LLC acquired a new position in Fate Therapeutics in the second quarter valued at approximately $1,133,000. 97.54% of the stock is owned by institutional investors and hedge funds.

Fate Therapeutics Stock Up 1.2 %

NASDAQ FATE opened at $1.68 on Friday. The company has a market capitalization of $191.34 million, a price-to-earnings ratio of -1.02 and a beta of 1.95. Fate Therapeutics, Inc. has a twelve month low of $1.59 and a twelve month high of $8.83. The stock has a fifty day simple moving average of $2.56 and a 200 day simple moving average of $3.34.

Fate Therapeutics (NASDAQ:FATE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.02. The firm had revenue of $3.07 million during the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. Research analysts expect that Fate Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on FATE shares. Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research report on Monday, November 18th. Needham & Company LLC restated a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Finally, Wedbush reaffirmed a “neutral” rating and issued a $5.00 target price on shares of Fate Therapeutics in a research note on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Fate Therapeutics presently has an average rating of “Hold” and an average price target of $6.75.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.